Jun-ichi Suzuki, Masahito Ogawa, Susumu Muto, Akiko Itai, Mitsuaki Isobe, Yasunobu Hirata, Ryozo Nagai
University of Tokyo, Graduate School of Medicine, Department of Advanced Clinical Science and Therapeutics, Tokyo, Japan.
Expert opinion on investigational drugs 2011 MarNF-kB is a key regulator of inflammation and immunity in cancer development. The IkB kinase (IKK) is a multisubunit complex containing catalytic subunits termed IKK-α, -β and -γ. It is well known that many pro-inflammatory stimuli require the IKK-β subunit for NF-kB activation. NF-kB affects the progression of inflammation-related diseases,such as myocardial ischemia, bronchial asthma, arthritis, cancer and other diseases. We review the characteristics and effects of these inhibitors on inflammatory and other diseases. Various synthesized IKK inhibitors have been developed and they will be used clinically in the near future.
Jun-ichi Suzuki, Masahito Ogawa, Susumu Muto, Akiko Itai, Mitsuaki Isobe, Yasunobu Hirata, Ryozo Nagai. Novel IkB kinase inhibitors for treatment of nuclear factor-kB-related diseases. Expert opinion on investigational drugs. 2011 Mar;20(3):395-405
PMID: 21314234
View Full Text